A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
Clinical trial NCT04641754 · UNKNOWN
Trial details
- NCT number
- NCT04641754
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-07
- Primary completion
- 2020-12-01
- Enrollment
- 176
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.